Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with α-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 11, 2007, Pages 1019-1026

  Chalmers, Katy A ^a   Love, Seth ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Synucleinopathy; Corticobasal degeneration; Pick disease; Progressive supranuclear palsy; Smad signaling; Tauopathy; Transforming growth factor (TGF )

Indexed keywords

AGED; ARTICLE; BRAIN TISSUE; CELL INCLUSION; CELL NUCLEUS; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; CYTOPLASM; DATA ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GLIA CELL; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN BINDING; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BLOTTING, WESTERN; BRAIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; LEWY BODY DISEASE; MALE; MULTIPLE SYSTEM ATROPHY; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PICK DISEASE OF THE BRAIN; PROTEIN TRANSPORT; SMAD PROTEINS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 35848936947     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e31815885ad     Document Type: Article

References (13)

1. Hata A, Shi Y, Massague J. TGF-β signaling and cancer: Structural and functional consequences of mutations in Smads. Mol Med Today 1998;4:257
2. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990;346:371-74
3. Van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993;4:69-72
4. Flanders KC, Ren RF, Lippa CF. Transforming growth factor-βs in neurodegenerative disease. Prog Neurobiol 1998;54:71-85
5. Peress NS, Perillo E. Differential expression of TGF-β 1, 2 and 3 isotypes in Alzheimer's disease: A comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 1995;54:802-11
6. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-A1 in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6
7. Chalmers KA, Love S. Neurofibrillary tangles may interfere with Smad 2/3 signaling in neurons. J Neuropathol Exp Neurol 2007;66:158-67
8. Lee HG, Ueda M, Zhu X, Perry G, Smith MA. Ectopic expression of phospho-Smad2 in Alzheimer's disease: Uncoupling of the transforming growth factor-β pathway? J Neurosci Res 2006;84:1856-61
9. Ueberham U, Ueberham E, Gruschka H, Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer's disease. Eur J Neurosci 2006;24:2327-34
10. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGFβ activity. Mol Cell 2000;5:27-34
11. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519
12. King ME, Ghoshal N, Wall JS, Binder LI, Ksiezak-Reding H. Structural analysis of Pick's disease-derived and in vitro-assembled tau filaments. Am J Pathol 2001;158:1481-90
13. Arima K. Ultrastructural characteristics of tau filaments in tauopathies: Immuno-electron microscopic demonstration of tau filaments in tauopathies. Neuropathology 2006;26:475-83